GPR160 and infection: Polyomaviruses, flaviviruses, influenza virus, and SARS-CoV-2 activate and/or require GPCR-mediated pathways for cell infection, including MAPK [116], suggesting that GPR160 could become an attractive target for the development of broad CD antiviral therapies.